上尿路尿路上皮癌内镜保肾手术前的风险分层:一项国际协作研究
该回顾性协作研究纳入1214例2000–2017年间接受输尿管镜活检后行根治性肾输尿管切除术的非转移性上尿路尿路上皮癌患者,构建预测≥pT2/N+的优化模型。模型纳入年龄、高级别活检、活检cT1+分期、术前肾积水、肿瘤大小、影像学侵犯和广基结构,准确率75%优于现有模型(66–71%),每100例患者额外获得4例临床净获益。
要点
- 年龄、高级别活检、活检cT1+、术前肾积水、肿瘤大小、影像学侵犯、广基结构与≥pT2/N+独立相关。
- 新模型预测≥pT2/N+准确率75%,优于现有未验证模型(66–71%)。
- 新模型每100例患者额外获得4例临床净获益,有助于筛选内镜保肾手术候选者。
核心结论
- 所提出的风险分层模型能可靠预测上尿路尿路上皮癌存在≥pT2/N+的风险,临床净获益优于现有风险分层模型。
研究设计与样本
- 国际协作回顾性研究,纳入1214例2000–2017年间接受输尿管镜活检后行根治性肾输尿管切除术的非转移性上尿路尿路上皮癌患者。
- 采用链式方程多重插补处理缺失数据,多变量逻辑回归结合逐步选择算法构建最优预测模型,用AUC和决策曲线分析比较模型。
主要发现
- 659例(54.3%)为≤pT1N0/Nx,555例(45.7%)为≥pT2/N+。
- 多变量分析中年龄OR 1.02(95%CI 1.0–1.03,p=0.013)、高级别活检OR 1.81(95%CI 1.37–2.40,p<0.001)、活检cT1+分期OR 3.23(95%CI 1.93–5.41,p<0.001)与≥pT2/pN+显著相关。
- 术前肾积水OR 1.37(95%CI 1.04–1.80,p=0.024)、肿瘤大小OR 1.09(95%CI 1.01–1.17,p=0.029)、影像学侵犯OR 5.10(95%CI 3.32–7.81,p<0.001)、广基结构OR 2.31(95%CI 1.58–3.36,p<0.001)与≥pT2/pN+显著相关。
- 新模型准确率75%,优于现有模型的66–71%,每100例患者额外获得4例临床净获益。
临床怎么用
- 对于拟行内镜保肾手术的上尿路尿路上皮癌患者,可依据年龄、活检分级与分期、术前肾积水、肿瘤大小、影像学侵犯及广基结构评估≥pT2/N+风险。
- 新模型准确率75%且临床净获益优于现有模型,可用于辅助筛选适合内镜保肾手术的低风险患者。
局限性
- 本研究为回顾性协作研究,结论需外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Several groups have proposed features to identify low-risk patients who may benefit from endoscopic kidney-sparing surgery in upper tract urothelial carcinoma (UTUC). OBJECTIVE: To evaluate standard risk stratification features, develop an optimal model to identify ≥pT2/N+ stage at radical nephroureterectomy (RNU), and compare it with the existing unvalidated models. DESIGN, SETTING, AND PARTICIPANTS: This was a collaborative retrospective study that included 1214 patients who underwent ureterorenoscopy with biopsy followed by RNU for nonmetastatic UTUC between 2000 and 2017. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We performed multiple imputation of chained equations for missing data and multivariable logistic regression analysis with a stepwise selection algorithm to create the optimal predictive model. The area under the curve and a decision curve analysis were used to compare the models. RESULTS AND LIMITATIONS: Overall, 659 (54.3%) and 555 (45.7%) patients had ≤pT1N0/Nx and ≥pT2/N+ disease, respectively. In the multivariable logistic regression analysis of our model, age (odds ratio [OR] 1.02, 95% confidence interval [CI] 1.0-1.03, p = 0.013), high-grade biopsy (OR 1.81, 95% CI 1.37-2.40, p < 0.001), biopsy cT1+ staging (OR 3.23, 95% CI 1.93-5.41, p < 0.001), preoperative hydronephrosis (OR 1.37 95% CI 1.04-1.80, p = 0.024), tumor size (OR 1.09, 95% CI 1.01-1.17, p = 0.029), invasion on imaging (OR 5.10, 95% CI 3.32-7.81, p < 0.001), and sessile architecture (OR 2.31, 95% CI 1.58-3.36, p < 0.001) were significantly associated with ≥pT2/pN+ disease. Compared with the existing models, our model had the highest performance accuracy (75% vs 66-71%) and an additional clinical net reduction (four per 100 patients). CONCLUSIONS: Our proposed risk-stratification model predicts the risk of harboring ≥pT2/N+ UTUC with reliable accuracy and a clinical net benefit outperforming the current risk-stratification models. PATIENT SUMMARY: We developed a risk stratification model to better identify patients for endoscopic kidney-sparing surgery in upper tract urothelial carcinoma.
引用
- Foerster B, Abufaraj M, Matin SF, et al. Pretreatment Risk Stratification for Endoscopic Kidney-sparing Surgery in Upper Tract Urothelial Carcinoma: An International Collaborative Study. Eur Urol. 2021. PMID: 34023164. doi:10.1016/j.eururo.2021.05.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。